相关实验视频
Updated: Jul 6, 2026

09:27
The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat
Published on: June 17, 2016
12.0K
素诱导的肝损伤:一个案例报告
Rui Ribeiro1, Judite Antas1, Ana Pais Monteiro1
1Internal Medicine, Centro Hospitalar Universitário de Santo António, Porto, PRT.
Cureus
|April 4, 2024
概括
福斯福米是一种用于尿路感染的抗生素,可导致肝损伤. 一份病例报告详细介绍了一个病人.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
背景情况:
- 斯福米是一种广泛用于无并发性尿路感染的抗生素.
- 虽然一般耐受性很好,但报告有罕见的肝损伤病例.
研究的目的:
- 报告与斯福米辛使用相关的急性肝损伤病例.
- 要强调氏素的潜在肝毒性以及在药物诱导性肝损伤 (DILI) 中考虑它的重要性.
主要方法:
- 一个73岁的女性患者的病例报告.
- 临床表现,实验室发现和肝损伤的诊断工作.
- 排除肝炎的其他原因,包括病毒,自身免疫和胆道病因.
主要成果:
- 患者在开始服用斯福米辛6天后出现了缺乏症状的肝细胞急性肝损伤.
- 药物诱导性肝损伤 (DILI) 的诊断,在排除其他原因后归因于福米.
- 一周内显著的临床改善,一个月内肝损伤完全消失.
结论:
- 斯福米辛可能与药物诱导的肝损伤 (DILI) 相关.
- 在治疗后出现肝损伤的患者中,应考虑肝毒性.
- 及时诊断和停止使用违规剂有助于恢复.
相关概念视频
Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Drug Toxicity: Overview
Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

